Neogenomics (NEO) Change in Accured Expenses (2010 - 2026)

Neogenomics (NEO) has 17 years of Change in Accured Expenses data on file, last reported at $15.7 million in Q2 2026.

• Quarterly Change in Accured Expenses rose 82.07% year-over-year to $15.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $7.4 million (up 10322.22% YoY) and the FY2025 annual result came in at -$15.7 million, down 268.75% from the prior year.
• Change in Accured Expenses grew to $15.7 million in Q2 2026, from -$7.0 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.7 million in Q2 2026 to a low of -$23.0 million in Q1 2025.
• A 5-year average of $953333.3 and a median of $2.5 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 194.88% — and 2024, when it tumbled 155.89%.
• Tracing NEO's Change in Accured Expenses over 5 years: stood at $2.2 million in 2022, then soared by 158.93% to $5.6 million in 2023, then surged by 84.64% to $10.3 million in 2024, then sank by 139.87% to -$4.1 million in 2025, then jumped by 482.85% to $15.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $15.7 million (Q2 2026), -$7.0 million (Q1 2026), and -$4.1 million (Q4 2025), per Business Quant data.